Purpose: To identify changes in plasma cytokine levels after image-guided thermal ablation of human tumors and to identify the factors that independently predict changes in plasma cytokine levels.
Image-guided thermal ablation offers patients a repeatable and low-morbidity treatment that has been shown to palliate, salvage, or cure both primary and metastatic malignancies effectively (1) (2) (3) . Heat-based thermal ablation (radiofrequency ablation and microwave ablation) kills tumors via direct thermal denaturation and coagulation of tumor proteins (4) . Cold-based thermal ablation (cryoablation) relies on the formation of intracellular ice crystals that arrest tumor cell function by damaging intracellular organelles and disrupting the plasma membranes of tumor cells (5) . All thermal ablation techniques leave devitalized and damaged tumor cells within the body, stimulating a robust inflammatory response demonstrating the cardinal signs of inflammation, including fever, pain, and swelling in ablated tissues (6) . This inflammatory response can be seen radiologically (7) and pathologically (8) .
Thermal ablation creates an internal wound that initiates a stereotypic wound healing response consisting of inflammatory, proliferative, and maturational phases mediated by growth factors and cytokines (9) . After thermal injury, activated platelets release interleukin (IL)-1, tumor necrosis factor (TNF)-α, and transforming growth factor-β, which increase vascular permeability and promote chemotaxis. Neutrophils are attracted to the region and perform debris scavenging by releasing free radicals via oxidative burst mechanisms aimed at destroying inciting agents (cellular debris and foreign cells). Macrophage migration ensues, transitioning to the proliferative stage, during which macrophages secrete growth factors (10) , including TNF-α, vascular endothelial growth factor, and basic fibroblast growth factor. Tissue remodeling factors such as hepatocyte growth factor (also known as scatter factor) and matrix metalloproteinases degrade stroma, facilitating cellular motility and granulation tissue formation. The level of proliferative activity of macrophages and lymphocytes is mediated by IL-6 positively (11) and IL-10 negatively (12) .
In the event of an incomplete ablation or multifocal disease, viable tumor cells (in the sublethal ablation margin or at a remote site of disease) may be affected positively or negatively by the concomitant inflammatory response including increased levels of cytokines (eg, IL-6) (13) and growth factors (eg, hepatocyte growth factor) (14) . Inflammation may augment tumor cell death by increasing neutrophil infiltration and subsequent destruction of the tumor cells by oxidative burst mechanisms, similar to mechanisms for the destruction of bacterial pathogens (15) . Inflammation following ablation may have negative effects via the production of growth factors and cytokines by macrophages and lymphocytes, which could stimulate tumor cell growth within the sublethal margin (16) .
Isolated human and animal studies of immunohistochemical staining of tissues, enzyme-linked immunosorbent assay of tissue lysates, and enzyme-linked immunosorbent assay of plasma have shown 2-fold-150-fold changes in specific inflammatory and immunomodulatory mediators after thermal ablation (17) (18) (19) (20) (21) (22) . However, it is unknown how tumor characteristics (eg, tumor site, primary diagnosis, metastatic status) and ablation characteristics (eg, modality, ablation size, time from ablation) affect plasma cytokine levels after ablation. The purpose of this study is to identify changes in plasma cytokine levels after image-guided thermal ablation of human tumors and to identify the factors that independently predict changes in plasma cytokine levels using multivariate analysis.
MATERIALS AND METHODS

Patients
Institutional review board approval was obtained for this prospective biospecimen study. The inclusion criterion was planned thermal ablation in patients being treated for primary or secondary malignancy. Exclusion criteria included prior ablation or embolization procedure within 30 days, combined embolization and ablation procedure, and patients who did not require clinical blood testing before the procedure. Using these criteria, between February 2011 and July 2011, 49 patients were recruited and consented to participate in the study. For patients consenting to the study, in accordance with our institutional biospecimen protocol, research blood draws were obtained at the time of a patient's clinical blood draws. Under this biospecimen protocol, if clinical blood draws were not indicated at a particular time point, research blood samples were not drawn. Of the 49 patients, 4 patients subsequently withdrew from the study or refused the research blood draws, and 9 patients were discharged on the same day of the procedure and did not undergo laboratory testing after the procedure. The remaining 36 patients were evaluated.
Patient demographics and ablation details are listed in Table 1 . The mean age of patients was 63.4 years. The most common primary diagnosis was colorectal cancer (39%), followed by sarcoma (22%), liver (11%), head and neck (8%), lung (8%), melanoma (6%), kidney (6%) and gynecologic (1%) malignancies. Most ablations were performed in liver (42%) or lung (44%). Ablations were predominantly heat-based (89% microwave, laser, or radiofrequency ablation); 11% of ablations were coldbased (cryoablation).
Thermal Ablation
All tumors were treated using thermal ablation performed under general anesthesia and using sterile technique. A single dose of prophylactic antibiotic (Ancef; GlaxoSmithKline, Research Triangle Park, North Carolina) was administered intravenously before the procedure. The skin and subcutaneous tissue were infiltrated with lidocaine 1%. Type of thermal ablation and protocol were determined by operator preference, tumor size, geometry, and location. Using computed tomography (CT) or magnetic resonance (MR) imaging guidance, the applicator was guided to the tumor and positioned to create an adequate margin around the tumor. When necessary, multiplanar reconstructions were performed to confirm that the planned ablation zone would encompass the tumor. Radiofrequency ablation was performed using the Radiotherapeutics (Boston Scientific, Natick, When the ablation device was appropriately positioned, ablation was performed. The endpoint of ablation in all cases was creation of an ablation zone with a margin of at least 5 mm circumferentially around the tumor (23) . When necessary, the ablation probe was repositioned, and further ablation was performed to achieve the desired endpoint.
Immediately after ablation, non-contrast-enhanced CT (for lung) or contrast-enhanced CT (for liver and other sites) was performed to confirm the ablation zone. In the case of lung ablation, chest radiographs were also obtained immediately and 2 hours after the procedure to evaluate for pneumothorax. All cases of enlarging or symptomatic pneumothoraces were managed with a pigtail thoracostomy catheter. The patients recovered in the postanesthesia care unit and were observed for a minimum of 24 hours. Follow-up CT or MR imaging was performed within 4-6 weeks. The ablation diameter was defined as the maximum length of the zone of nonenhancement on contrastenhanced CT after the procedure or, in the case of lung ablation, the size of ground-glass or lung consolidation after the procedure, as measured on axial imaging. In the case of multiple sites of ablation, the maximum diameter of each ablation site was summed. The size of the ablation zone was defined as the maximum area of the zone of nonenhancement on contrast-enhanced CT after the procedure or, in the case of lung ablation, the size of ground-glass or lung consolidation after the procedure, as measured on axial imaging.
Cytokine Measurement
Before the procedure, 36 patients underwent research blood draws in conjunction with a clinical blood draw. After the procedure, 33 of 36 patients underwent a blood draw in conjunction with a clinical blood draw within 48 hours of ablation. At follow-up, 21 of 36 patients underwent a research blood draw in conjunction with standard of care blood work. There were 90 research blood samples obtained. Whole-blood samples were collected in tubes with calcium-ethylenediamine tetraacetic acid, transported to our clinical chemistry laboratory certified by the Clinical Laboratory Improvement Amendments, and centrifuged to obtain plasma. Plasma samples were stored at−801 C until analysis.
Plasma levels of inflammatory mediators were measured using the SearchLight Multiplex Immunoassay system (Aushon Biosystems, Billerica, Massachusetts). Plasma levels of IL-1α, IL-2, IL-6, IL-10, and TNF-α were measured. Plasma white blood cell (WBC) count was also measured automatically using the ADVIA 2120 Hematology System (Siemens Healthcare Diagnostics, Erlangen, Germany) using both flow cytometry and the peroxidase method.
Statistical Analysis
Fold changes of cytokine levels and WBC count were computed compared with levels obtained before ablation. Univariate analysis of mediator level as outcome was performed on the 90 samples for patient and ablation variables. Because most patients received multiple blood draws, sampling time (before ablation, after ablation, and follow-up) was treated as repeated measures variables. The subject variable was treated as a random effect. For mediators that showed a significant change after ablation, multivariate linear regression was performed for patient and ablation variables to identify the factors that were independent predictors of the change. Significance level was defined as Po .05. All analyses were performed in SAS (version 9.2; SAS Institute Inc, Cary, North Carolina).
RESULTS
On average, blood draws were obtained−7.1 days Ϯ 5.7 before ablation. The mean time to the blood draw after thermal ablation was 0.8 days Ϯ 0.2 ( Table 1) . Mean time to follow-up blood draws was 16.6 days Ϯ 9.2. The average ablation size was 13.8 cm 2 Ϯ 7.6. The plasma levels of IL-6 and IL-10 showed robust changes after ablation (Table 2, Fig) . IL-6 levels increased significantly from 16.7 to 46.6 pg/mL (P ¼ .002), and IL-10 increased from 1.9 to 3.3 pg/mL (P ¼ .02). WBC count also increased significantly immediately after ablation, from 6.0 to 7.6 K/mcL (P ¼ .0003). IL-1α, IL-2, and TNF-α showed no significant changes in levels 48 hours after ablation. At follow-up 1-5 weeks after ablation, neither cytokine levels nor WBC count showed a significant change from values before ablation.
To identify relationships between changes in cytokine levels after ablation and other factors, tabulation of the fold change for cytokine levels after ablation was performed, with stratification by primary diagnosis, metastatic status, ablation site, ablation type, and ablation size ( Table 3 ). The largest changes were seen in plasma levels of IL-6. With regard to diagnosis, ablation of melanomas showed the largest increase in IL-6 levels (92-fold) o48 hours after ablation, followed by ablation of kidney (26-fold), liver (8-fold), and lung (5-fold) malignancies. With regard to ablation site, ablation of bone and kidney produced the greatest fold change in IL-6 levels o 48 hours after ablation (91-fold and 26-fold, respectively). Cryoablation showed a significantly greater change in IL-6 levels compared with radiofrequency and microwave ablation (54-fold vs 3.6-fold and 3.4-fold, Po .0027 and Po .0034, respectively). Ablation size showed a nonlinear relationship between fold change and cytokine level, with ablations in the 10-20 To determine the factors that were predictors of cytokine level changes after thermal ablation, univariate analysis was performed on the cytokines that showed a significant overall effect (IL-6 and IL-10) and WBC count ( Table 4 ). Univariate analysis showed that age, primary diagnosis, ablation site, and ablation type were significant predictors of change in IL-6 and IL-10 levels after ablation. Primary tumor type (primary vs metastasis) also predicted changes in IL-10 level. In contrast, ablation size was the only predictor of WBC count increase after thermal ablation.
To determine which patient and ablation factors were independent predictors of changes in cytokine levels after thermal ablation, multivariate analysis was performed ( Table 5) . After controlling for the other variables, the only independent predictors of the IL-6 Values presented as mean Ϯ SD of fold change. Levels were measured after the procedure ( o 48 h, n ¼ 33). IL ¼ interleukin; TNF ¼ tumor necrosis factor; WBC ¼ white blood cell. level increase after ablation were primary diagnosis (P o.039) and ablation type (Po .0001). For IL-10, age remained the only independent factor and was a positive predictor of IL-10 level increase after ablation. Ablation size was the only independent positive predictor of WBC count increase after ablation (Po .015).
DISCUSSION
These results show that percutaneous thermal ablation of tumors invokes an inflammatory response that is characterized by elevation in the plasma levels of specific cytokines. IL-6 and IL-10 show the most robust increases in plasma levels within 48 hours of ablation, whereas TNF-α and IL-1 were unchanged. Both the type of ablation (particularly cryoablation) and the primary diagnosis (particularly melanoma, kidney, and liver cancers) have a profound impact on changes in IL-6 levels after percutaneous ablation. Our results are consistent with investigations of cytokine changes after open surgical ablation. Schell et al (18) showed that after open surgical radiofrequency ablation of hepatic malignancy, IL-6 levels increased 4-fold, and after open hepatic cryoablation, IL-6 levels increased4100-fold (20) . Similarly, Li et al (24) demonstrated lower elevations in IL-6 after highintensity focused ultrasound (a heat-based ablation technique) compared with prostate cryoablation. In our patient population undergoing image-guided ablation, heat-based ablation techniques showed 3.5-fold increases in IL-6 levels compared with a 54-fold increase with cryoablation. The higher levels of cytokines after open surgical ablation may be due to the increased inflammatory response from the larger incision required for open surgical ablation. In our patient population, differences in cytokine levels after heat-based and cold-based ablation techniques may be due to the fact that cryoablation results in the shattering of cellular membrane and less denaturation of proteins than the hydrolysis of proteins seen in heat-based ablation. This could potentially lead to increased deposition of tumor antigens into the extracellular space, serving as a stimulus for the inflammatory response. It is interesting to speculate to what degree non-thermal ablation techniques such as irreversible electroporation would elicit serum cytokine changes. Why the changes in WBC count showed a linear increase with ablation size but IL-6 levels did not is intriguing. It is possible that the size of ablation determines the degree of generalized inflammatory response, as indicated by the serum WBC count, but differences in tumor and ablation characteristics more profoundly affect the IL-6 level than ablation size.
IL-6 and IL-10 are categorized as T helper (Th) 2 cytokines because they are both produced by Th2 lymphocytes (25) , whereas IL-2 and TNF are categorized as Th1 cytokines because they are both produced by Th1 lymphocytes (26) . Our data showing that plasma levels of IL-6 and IL-10 (but not IL-2 and TNF-α) are elevated after thermal ablation support our hypothesis that the lymphocytes that infiltrate the site of thermal ablation (27) are predominantly a Th2 population. Our hypothesis is also supported by studies that show that Th2 cytokines promote fibrocyte differentiation (28) and fibrotic scar formation after hepatic injury (29) . Recovery after liver injury is mediated by the nuclear factor kappa light chain enhancer of activated B cells (NF-Kb) and signal transducer and activator of transcription 3 (STAT3) signaling pathways, both of which are activated by IL-6 (30). IL-6-deficient mice show impaired liver regeneration after partial hepatectomy, and treatment of mice with IL-6 before injury resulted in improved liver regeneration (31) . Recovery of soft tissues after injury is also dependent on IL-6; IL-6 knockout mice show markedly increased wound healing time after punch biopsy compared with controls (32) .
Cytokines such as IL-6 not only support the regeneration of normal liver parenchyma after injury but also directly support survival of cancer cells (33) . IL-6 has been shown to promote the growth of lung (34), colon (35) , liver (36) , and other cancers (37) (38) (39) . The relationship between IL-6 and the development of cancer is particularly strong in the liver, and increased levels of IL-6 may predispose patients with hepatitis to develop hepatocellular carcinoma (HCC). Patients with hepatitis B and a high plasma level of IL-6 (47 pg/mL) have a HCC-free survival three times shorter than patients with low IL-6 levels, even after controlling for age, gender, cirrhosis, use of antiviral treatments, hepatitis B virus DNA, and peak alanine aminotransferase levels (40) . In cultured HCC cells challenged with doxorubicin, IL-6 inhibition using an anti-IL-6 antibody resulted in more cell death than controls without IL-6 inhibition (41).
Our finding that IL-6 levels are increased after thermal ablation of tumors has several potential ramifications for both locoregional cancer therapy and systemic targeted therapy. Because focal ablation can induce high systemic levels of IL-6 after ablation, viable tumor cells that persist either in the margin of the ablation zone or remote from the ablation site may be inadvertently stimulated to proliferate by circulating IL-6. The development of adjuvant therapies that decrease IL-6 levels, increase IL-10 levels, or affect the downstream targets of these molecules (eg, STAT3) may prove useful in decreasing the rate of local recurrence or distant metastasis, or both, after thermal ablation. IL-6 and IL-10 are attractive potential targets for the development of adjuvant therapies, which could enhance the treatment efficacy of image-guided thermal ablation of tumors (42) . In addition, because thermal ablation leads to increases in both blood and ablation zone lymphocytes, immunotherapeutic strategies designed to shift the balance of lymphocytes from the Th2 phenotype (which produce IL-6) to the Th1 phenotype (which support cell-mediated tumor killing) may prove useful for future research (43) . This study has several limitations. Because of the observational nature of this study, certain subgroups have small samples, which skew the analyses and do not allow for rigorous hypothesis testing. Larger studies should be performed to validate these results and should focus on undersampled subpopulations in this study (eg, melanoma ablations) to confirm the observed cytokine changes. Cytokine blood specimens were obtained at the time of clinical blood draws rather than at fixed time points, which could lead to lack of precision in the average cytokine levels in the groups after ablation and at follow-up. Because assay of a limited panel of cytokines was performed, it is possible that the other relevant cytokines that play a vital role in shaping the microenvironment after ablation were omitted from the analysis. We hope that future studies of our existing plasma samples will allow for a more complete understanding of cytokine changes after thermal ablation. Other confounding variables were not measured (eg, ablation time, ablation power, number of ablations, use of anesthesia), which may affect the lack of significance of factors (eg, ablation size). Finally, plasma levels of cytokines are a surrogate marker only for changes in the ablation zone microenvironments, and local cytokine levels could vary greatly from levels in plasma. We hope to validate the presumed correlation between cytokine levels in plasma and biochemical changes in the local ablation zone with animal studies.
In conclusion, percutaneous thermal ablation of tumors resulted in increased plasma levels of IL-6 and IL-10 in the first 48 hours after ablation in our patient population. Cryoablation of tumors produces greater changes in IL-6 levels than heat-based ablation techniques.
